Vivek Jayaraman - Cerus Chief Commercial Officer
| CERS Stock | USD 1.82 0.03 1.68% |
Executive
Mr. Vivek K. Jayaraman is a Chief Commercial Officer of the CERUS CORPORATION. Mr. Jayaraman was appointed our Chief Commercial Officer in August 2016. From October 2009 to February 2016, Mr. Jayaraman served as Vice President, Sales and Marketing of TriVascular Technologies, Inc., or TriVascular, where he oversaw TriVasculars commercial expansion as the company grew from a preclinical, venturebacked startup into a publicly traded, global medical device company since 2016.
| Age | 49 |
| Tenure | 8 years |
| Professional Marks | MBA |
| Address | 1220 Concord Avenue, Concord, CA, United States, 94520 |
| Phone | 925 288 6000 |
| Web | https://www.cerus.com |
Cerus Management Efficiency
The company has return on total asset (ROA) of (0.0373) % which means that it has lost $0.0373 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.3831) %, meaning that it created substantial loss on money invested by shareholders. Cerus' management efficiency ratios could be used to measure how well Cerus manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.2 in 2024. Return On Capital Employed is likely to drop to -0.24 in 2024. At this time, Cerus' Non Current Assets Total are comparatively stable compared to the past year. Non Currrent Assets Other is likely to gain to about 34.3 M in 2024, whereas Total Current Assets are likely to drop slightly above 99.5 M in 2024.Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Dr JD | Cutera Inc | 53 | |
| Reay MD | Sight Sciences | N/A | |
| John Harris | Integer Holdings Corp | 64 | |
| MD FACS | Glaukos Corp | N/A | |
| Roberto Mezerville | Establishment Labs Holdings | 43 | |
| David JD | Pulmonx Corp | 63 | |
| Mark Karshner | Orthopediatrics Corp | N/A | |
| Taylor Erickson | Treace Medical Concepts | N/A | |
| Ivica MD | Axogen Inc | N/A | |
| Helen Leupold | Bioventus | N/A | |
| Rosalyn dIncelli | Establishment Labs Holdings | N/A | |
| David Crawford | Bioventus | N/A | |
| Julie Dewey | Orthofix Medical | 63 | |
| Lucas Vitale | Orthofix Medical | 47 | |
| Mu Lee | Accuray Incorporated | N/A | |
| Teryl Sides | SurModics | 54 | |
| Tom Huang | Sight Sciences | N/A | |
| Amy Treadwell | Neuropace | N/A | |
| Shana Zink | Treace Medical Concepts | N/A | |
| Jeremy JD | Sight Sciences | 54 | |
| Michael JD | Si Bone | 46 | |
Management Performance
| Return On Equity | -0.38 | ||||
| Return On Asset | -0.0373 |
Cerus Leadership Team
Elected by the shareholders, the Cerus' board of directors comprises two types of representatives: Cerus inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Cerus. The board's role is to monitor Cerus' management team and ensure that shareholders' interests are well served. Cerus' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Cerus' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Matthew Notarianni, Director Relations | ||
| Richard Benjamin, Chief Medical Officer | ||
| Kevin Green, CFO and VP of Fin. | ||
| William Greenman, CEO and President and Director | ||
| Carol Moore, Sr. VP of Regulatory Affairs, Quality and Clinical | ||
| Lainie Corten, Sr. Director, Global Marketing & Investor Relations | ||
| Vivek Jayaraman, Chief Commercial Officer | ||
| Chrystal Jensen, Chief Counsel | ||
| Laurence MD, CoFounder Officer | ||
| Jessica Hanover, Vice Affairs | ||
| Chrystal Menard, Chief Legal Officer | ||
| Lori Roll, VP Secretary | ||
| Kevin CPA, VP CFO | ||
| Dr MBChB, Chief Officer | ||
| Laurence Corash, Senior Vice President Chief Medical and Chief Scientific Officer, Director | ||
| Alicia Goodman, Chief Officer | ||
| Chrystal JD, Chief Counsel | ||
| Nina Mufti, Senior Development |
Cerus Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Cerus a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.38 | ||||
| Return On Asset | -0.0373 | ||||
| Profit Margin | (0.11) % | ||||
| Operating Margin | (0.02) % | ||||
| Current Valuation | 354.76 M | ||||
| Shares Outstanding | 185.72 M | ||||
| Shares Owned By Insiders | 3.27 % | ||||
| Shares Owned By Institutions | 79.26 % | ||||
| Number Of Shares Shorted | 7.93 M | ||||
| Price To Earning | (4.70) X |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Cerus Stock Analysis
When running Cerus' price analysis, check to measure Cerus' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Cerus is operating at the current time. Most of Cerus' value examination focuses on studying past and present price action to predict the probability of Cerus' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Cerus' price. Additionally, you may evaluate how the addition of Cerus to your portfolios can decrease your overall portfolio volatility.